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ABSTRACT
Therapeutic benefits from nociceptin opioid peptide receptor (NOP)
antagonism were proposed for obesity, eating disorders, and
depression. LY2940094 ([2-[4-[(2-chloro-4,4-difluoro-spiro[5H-
thieno[2,3-c]pyran-7,4ʹ-piperidine]-1ʹ-yl)methyl]-3-methyl-pyrazol-1-yl]-
3-pyridyl]methanol) is a novel, orally bioavailable, potent, and selective
NOP antagonist. We studied NOP receptor occupancy (RO) after single
oral LY2940094 doses in rat hypothalamus and human brain by use of
liquid chromatography with tandem mass spectrometry (LC-MS/MS)
(LSN2810397) and positron emission tomography (PET) ([11C]NOP-1A)
tracers, respectively. A bolusplus constant infusion tracer protocolwith
PETwas employed in humans at 2.5 and 26.5 hours after administration
of the LY2940094 dose. The RO was calculated from the change in
regional distributional volume (VT) corrected for nondisplaceable
volume using Lasson plots. The RO followed a simple Emax relationship
to plasma LY2940094 concentration, reaching near complete occu-
pancy in both species. For rat hypothalamus, the plasma concentration
at half-maximum RO (EC50) was 5.8 ng/ml. In humans, LY2940094 was
well tolerated and safe over the 4–40 mg dose range, and it peaked in
plasma at 2 to 6 hours after a 1- to 2-hour lag, with approximate dose-
proportional exposure. After 4–40 mg doses, NOP RO was similar
across the prefrontal cortex, occipital cortex, putamen, and thalamus,
with EC50 of 2.94 to 3.46 ng/ml, less than 2-fold lower than in rats. Over
4–40 mg doses, LY2940094 mean plasma levels at peak and 24 hours
were 7.93–102 and 1.17–14.1 ng/ml, corresponding to the cross-region
averageNOPROof 73%–97%and28%–82%, respectively. The rat EC50
translates well to humans. LY2940094 readily penetrates the human
brain, and a once-daily oral dose of 40 mg achieves sustainably high
(>80%) NOP RO levels suitable for testing clinical efficacy.
Introduction
Nociceptin/orphanin FQ (nociceptin) is a 17-amino acid neuropeptide
that acts as an endogenous ligand for the opioid-like one receptor
(ORL1), also known as NOP (nociceptin opioid peptide receptor). NOP
is a class A G-protein–coupled receptor (Meunier et al., 1995;
Reinscheid et al., 1995), is encoded by the gene opiate receptor-like
1 (OPRL1), and is widely expressed in the central nervous system and
specifically in regions associated with mood disorders and obesity.
Symptoms of many neuropsychiatric disorders, such as pain, anxiety,
depression, anorexia, obesity, and drug abuse, are believed to be poten-
tially linked to the NOP receptor (Lambert, 2008; Murphy, 2010), which
suggests NOP antagonism as a potential therapeutic strategy (Gavioli and
Calo, 2006; Witkin et al., 2014).
Interest in the target has spurred the discovery of multiple tracers.
Hostetler et al. (2013) reported the discovery of [18F]MK-0911, a potent,
selective, and brain-penetrant positron emission tomography (PET)
tracer, which was shown to have NOP binding in monkeys and humans,
and was displaceable by the potent NOP antagonist MK-5757. We have
recently discovered both labeled and unlabeled NOP receptor tracers
with subnanomolar binding affinities with no intrinsic activity (i.e.,
antagonists), high selectivity, central nervous system penetration, and
low nonspecific binding (Pedregal et al., 2012). LSN2810397 [Com-
pound (S)-27 in Pedregal et al., 2012; NOP Ki = 0.114 nM] is an
unlabeled tracer based on liquid chromatography with tandem mass
spectrometry (LC-MS/MS), and [11C]NOP-1A (Kimura et al., 2011;
Lohith et al., 2012, 2014; Pike et al., 2011) is a labeled tracer (NOP Ki =
0.15 nM) that lacks brain-penetrant radiometabolites and is suitable for
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PET studies. The two tracers are similar structurally, differing only in the
presence or absence of one N-substituted methyl. In humans, [11C]NOP-
1A is safe, with favorable kinetics and reproducibility (Lohith et al.,
2012, 2014), and exhibits a distribution volume (VT) consistent with
known NOP density distribution (Berthele et al., 2003).
Potent and selective NOP antagonists based on the dihydrospiro
(piperidine-4,7ʹ-thieno[2,3-c]pyran) chemical scaffold have been
recently discovered (Toledo et al., 2014). Among these, ([2-[4-[(2-
chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4ʹ-piperidine]-1ʹ-
yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol), referred to as
LY2940094 (Statnick et al., 2016) (Compound 36 in Toledo et al., 2014;
NOP Ki = 0.105 nM), was advanced to clinical development for the
treatment of depression and alcohol dependence.
We assessed the brain NOP receptor occupancy (RO) after single oral
administration of a range of doses of LY2940094 to healthy volunteers
using [11C]NOP-1A as a PET ligand, and examined the relationship
between the NOP RO levels of LY2940094 and its plasma concentra-
tions to support dose selection for future efficacy trials. Furthermore, we
assessed the translatability of the concentration-RO relationship of
LY2940094 between that in rats (using LSN2810397 as the LC-MS/MS–
based tracer) and humans (using [11C]NOP-1A and PET imaging).
Materials and Methods
Preclinical Studies of LY2940094 NOP RO in Rats. The NOP RO of
LY2940094 (Eli Lilly and Company, Indianapolis, IN) was evaluated in the
hypothalamus in both dose–response and time-course experiments. Male
Sprague-Dawley rats (230–300 g; three to four per dose group or time point)
were housed on a 12-hour light/dark cycle (testing during light phase) and
received free access to normal rat chow and water. Animals received either
vehicle, the reference NOP antagonist (5S,7S)-7-[[4-(2,6-dichlorophenyl)-
piperidin-1-yl]methyl]-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol (SB-
612111, 30 mg/kg, oral by gavage; Eli Lilly and Company) as a positive control
(Spagnolo et al., 2007), or LY2940094 (0.01–10 mg/kg for the dose–response
experiment; 1 mg/kg for the time-course experiment). For the dose–response
experiment, NOP RO was assessed at 6 hours after dose administration; for the
time-course experiment, NOPROwas assessed at 0.083, 0.25, 1, 2, 4, 8, and 24 hours
after dose administration. All experiments were conducted in compliance with the
Guide for the Care and Use of Laboratory Animals under protocols approved by a
local animal care and use committee.
For every RO assessment, 3 mg/kg of the tracer LSN2810397 (Eli Lilly and
Company) was administered intravenously 40 minutes before sacrificing the
animals. Tracer concentrations in the harvested hypothalamus, a region with high
NOP expression (Neal et al., 1999; Florin et al., 2000), were assessed as
previously described elsewhere (Pedregal et al., 2012; Toledo et al., 2014). The
brain tissue (time-course study) and plasma (both studies) LY2940094 concen-
tration were determined by use of a specific and validated LC-MS/MS method
that uses a 1200 HPLC apparatus (high-performance liquid chromatography;
Agilent Technologies, Palo Alto, CA) linked to an API 4000 mass spectrometer
(Applied Biosystems, Foster City, CA). A C18 column (2.1 mm  50 mm; part
no. 971700-907; Agilent Technologies) was used for the HPLC.
Because no true null region devoid of the NOP receptor was discerned in rat
brain, the ratio method for target occupancy calculations could not be employed.
To define 100% occupancy, or full blockade of specific binding, the hypothalamic
tracer levels (ng/g) of a positive control group were used. Previous experiments
determined that an oral dose of 30 mg/kg of SB-612111 fully blocked the tracer
LSN2810397 (Pedregal et al., 2012). The vehicle group ng/g tracer levels in the
hypothalamus represented 0% occupancy. The hypothalamic tracer levels of
cohorts of animals receiving LY2940094 were linearly interpolated based on the
slope of the line between the tracer levels of the vehicle (0%) and positive control
(100%) groups to obtain occupancy values based on the ng/g of tracer measured.
Clinical Study Design. The single-dose PET study used an open-label,
nonrandomized, and adaptive study design and was conducted on sequential
cohorts of healthy participants, enrolling a total of 14 healthy men, of whom
12 completed all the study procedures (3 per dose level). The participants were
men between 18 and 45 years of age (inclusive) in good health. Five of the
participants (41.7%) were white, 6 (50.0%) were black or African American, and
1 (8.3%) was Asian. A more complete list of entry criteria can be found at
clinicaltrials.gov, identifier: NCT01404091.
Participant recruitment and monitoring was conducted at Kendle Early Stage
(Toronto, Canada), and human neuroimaging was conducted at the Centre for
Addiction andMental Health (CAMH)Research ImagingCentre, Toronto, Canada.
The PET scans were performed at baseline and approximately 2.5 and 26.5 hours
after dose administration over two visits. The participants consented to the protocol
before their inclusion, the study was approved by the institutional review boards of
Kendle Early Stage and CAMH, and it was performed in accordance with the
ethical standards laid down in the 1964 Declaration of Helsinki.
There were four cohorts of subjects. The first cohort of three subjects received
40 mg of LY2940094, and the subsequent cohorts received dose levels that were
selected based on accumulated RO data in the study, with the objective of exploring
a wide dynamic range of RO. Cohort 2 and 3 subjects (n = 3 each) received 10 and
4 mg, respectively, and cohort 4 subjects received 20 mg (n = 2) and 40 mg (n = 1).
Safety was monitored regularly, including adverse events (AEs), vital signs,
electrocardiograms, physical examinations, clinical laboratory tests, the Columbia
Suicide Severity Rating Scale, and other routine laboratory tests.
Radiotracer [11C]NOP-1A. [11C]NOP-1Awas synthesized and formulated in
the radiochemistry laboratory of the CAMH PET Centre (Toronto, Canada) by
11C-methylation of an N-desmethyl precursor (Eli Lilly and Company), as
previously described in detail (Pike et al., 2011), and it was administered within
60 minutes after the completion of radiosynthesis through an indwelling catheter
in the antecubital vein, during which the radiotracer is known to be stable.
[11C]NOP-1Awas administered as an intravenous bolus plus constant infusion
over the 2-hour scan.We followed publishedmethods to determine themagnitude
of bolus fraction (i.e., Kbol) to be equivalent to 70 minutes of constant infusion
(Carson et al., 1993). Previous assessments have demonstrated that approximate
steady-state conditions could be consistently achieved (R. Innis, personal commu-
nication, 2011) using this regimen. The average total injected dose of radioactivity
for the PET radiotracer was less than 20 mCi (740 MBq) of [11C]NOP-1A, which
along with the transmission scan corresponded to less than 3.382 mSv per scan and
less than 10.15 mSv for the study.
Magnetic Resonance Imaging and PET Image Acquisition Procedures.
The emission PET images were acquired on a whole body PET camera system,
Siemens-Biograph HiRez XVI (Siemens Molecular Imaging, Knoxville, TN).
Magnetic resonance imaging (MRI) scans were obtained before the PET scanning
procedures to coregister the PET and MRI images for analysis of the PET data to
identify the volumes of interest using an automated method verified by visual
inspection (Rusjan et al., 2006). Additional details regarding the MRI and PET
image acquisition can be found in Supplemental Fig. 3.
One arterial blood sample was collected during the PET scanning after a steady
state had been reached (mean 6 S.D. = 59 6 11 minutes) after the radiotracer
injection. The parent fraction was measured by HPLC to determine the metabolite
corrected plasma input function, as previously described elsewhere (Lohith et al.,
2012). Sample chromatogram can be found in Supplemental Fig. 4.
Distribution Volume and RO Determination. PET tracer distribution
volume (VT) was estimated in multiple brain regions: putamen, caudate, occipital
cortex, prefrontal cortex, thalamus, and cerebellum. VT, representing the sum of
specific and nonspecific binding (Ichise et al., 2001; Innis et al., 2007),was determined
as the ratio of the average tracer concentration in the brain (Ct) during steady state
divided by the tracer concentration in plasma (Cp). For the four regions of interest
(ROI), namely, the prefrontal and occipital cortices, putamen, and thalamus, the NOP
RO by LY2940094 (OROI












drug, and VND are the total distribution volume before
(baseline) and after LY290094 administration and nondisplaceable volume,
respectively.
The nondisplaceable volume (VND) was estimated as the intercept of the Lassen
plots (Lassen et al., 1995; Cunningham et al., 2010), where the difference between
the baseline and blocked VT values is plotted against baseline VT for different
regions of the brain.
Plasma Concentrations and Pharmacokinetics of LY2940094. Venous
blood samples were collected in containers with an appropriate anticoagulant
before and after each scan as well as serially over a 24-hour period. LY2940094
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plasma concentrations were measured by a specific and validated LC-MS/MS
method. The prevailing LY2940094 concentration during the scan was calculated
as the average of the concentration before and after each scan. LY2940094
pharmacokinetic parameters were estimated using standard noncompartmental
analysis methods.
LY2940094 Plasma Concentration–NOP RO Relationship. The relation-
ship between the prevailing LY2940094 concentrations in plasma during the PET
scan and the OROI
drug values was characterized using a mixed-effect Emax model,
where Emax was fixed to the theoretical value of 100%. The model estimated EC50
values and additive intersubject and within-subject variances using SAS version
9.2 (SAS Institute, Cary, NC).
Results
LY2940094 NOP RO in Rat Brain. LY2940094 potently, dose-
dependently, and fully occupy the NOP receptor (Fig. 1A). In the time-
course study, LY2940094 plasma and brain concentrations were generally
parallel (Fig. 1B). Following its peak, RO followed an approximate linear
decline (Fig. 1C), maintaining .50% RO for at least 12 hours (by
interpolation). A linear decline in RO is typical when drug levels decline
exponentially, while the relationship between concentration and RO
follows an Emax model. The Emax fit to the NOP RO vs. plasma
LY2940094 levels (Fig. 1D) resulted in an EC506 SE estimate of 5.756
1.25 ng/mL.ROwas practically 100%between 5minutes and 2 hours post
dose, when LY2940094 was at its highest levels in plasma and brain
tissue, approximately 99–206 ng/mL and 84–123 ng/g, respectively.
LY2940094 Human Plasma Pharmacokinetics. LY2940094
plasma levels started to rise after a 1- to 2-hour lag time that was quite
variable across subjects (Fig. 2). Peak levels were achieved between 2
and 6 hours, followed by a biphasic decline: A rapid phase up to
approximately 12 hours, followed by a slow terminal phase.
The first postdose PET scan, which was a priori set at 2.5 hours to
coincide with the peak drug levels, appears to have occurred too early in
many subjects. The mismatch was most significant for the subjects
taking the 4- and 40-mg doses.
The pharmacokinetic parameter estimates for LY2940094 are sum-
marized in Table 1. Cmax and area under the plasma concentration–time
curve from 0 to 28.5 hours after dose administration (AUC0–28.5) values
appeared to increase approximately linearly as the LY2940094 dose
increased, although the sample size was too small to test this hypothesis
formally.
Radiosynthesis and Measurement in Plasma of [11C]NOP-1A.
Mean tracer specific activity of [11C]NOP-1A at the end of the synthesis
was 5720 mCi/mmol (S.D. = 1600 mCi/mmol), and the mean mass
injected was 1.57 mg (S.D. = 0.66 mg) with a radiochemical purity of
98.2% (S.D. = 1.0%). Parent [11C]NOP-1A typically formed 64% of the
total radioactivity in arterial blood samples.
[11C]NOP-1A Time-Activity Curves and LY2940094 NOP RO.
Sample PET images (Fig. 3) obtained from the same subject demon-
strated the overall brain uptake of [11C]NOP-1A and its blockade by
LY2940094.
Time-activity curves, presented as the ratio of radioactivity to the
parent-related radioactivity in plasma, are shown in Supplemental Fig. 1.
At baseline, the brain tracer uptake ratio levels in various regions of
interest rapidly increased upon the regimen initiation to a peak level
Fig. 1. NOP RO in rat hypothalamus after single oral dosing of LY2940094. (A) NOP RO 6 hours after dose administration as a function of dose, with Emax model fit (dotted
line). (B) Plasma and brain LY2940094 concentrations over time after 1 mg/kg dose. (C) Time course of NOP RO and brain concentration after 1 mg/kg dose. (D) NOP RO
as a function of time-matched LY2940094 plasma concentration, with Emax model fit (dotted line).
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typically after 10 to 20 minutes (due to the bolus) and subsequently
slightly decreased to steady-state levels. The steady-state level was
highest in receptor-richer regions like the thalamus, occipital cortex,
prefrontal cortex, and putamen, followed by the caudate and hippocam-
pus; that in the cerebellar cortex was the lowest. Postdose scans revealed
a reduction in radiotracer uptake (lower steady-state levels) that was
more profound after higher LY2940094 doses and in peak time scans,
which was consistent with the higher NOP blockade at higher plasma
concentrations.
Supplemental Figure 2 shows several typical Lassen plots obtained.
Linear regression fits were good, with R2 ranging between 0.83 and
0.99, except for one scan after the 4-mg dose where the relationship was
quite flat, indicating very low NOP occupancy.
Table 2 summarizes the mean NOPRO values by ROI, dose, and time
point. LY2940094 exhibited dose-dependent target engagement of the
NOP receptors after single oral doses (4–40 mg), exceeding 80% on
average in the top dose levels. The NOP RO seemed to decrease
moderately from the first to the second scan. The RO was similar across
the different brain ROIs.
The Emax model fitted the NOP RO-plasma concentration data well
(Fig. 4). Table 3 summarizes the derived parameters from model fits.
Safety. LY2940094 was safe and well tolerated after single admin-
istrations of doses ranging from 4–40 mg. There were no deaths, serious
AEs, or severe treatment-emergent adverse events (TEAEs). The overall
incidence of TEAEs was 25%. TEAEs were mild in severity, with no
relationship to dose, and were considered either unrelated or unlikely to
be related to LY2940094. The most frequent TEAE was vessel puncture
site pain, reported by two participants.
Discussion
We report here the results of our preclinical and clinical studies
designed to demonstrate the NOP RO by the novel potent and selective
NOP receptor antagonist LY2940094, which is currently under clinical
development for the treatment of depression. Our studies relied on a pair
of structurally similar NOP receptor tracers, LSN2810397 and [11C]NOP-
1A, both containing spiropiperidine, a common structural motif for NOP
antagonists (Toledo et al., 2014) that is also shared by LY2940094. The
studies examine the ability of rat NOP RO potency to predict human NOP
RO potency. Additionally, these studies shed light on key attributes of
LY2940094, including its systemic availability and pharmacokinetics,
brain penetration, and the level of NOPRO in various regions of interest in
the brain, providing a basis for dose selection for future development in
target indications.
Preclinical to Clinical Translation of NOP RO. In translational
drug development, it is desirable to use the RO results of a candidate
drug in preclinical species for predicting its human behavior (Melhem,
2013). Cross-species potency differences could arise from differences in
plasma protein binding, transport into the brain, and the degree of
receptor homology. Good cross-species concordance has been found in
multiple applications (Burns et al., 2007; Hostetler et al., 2013; Melhem,
2013). In others, significant differences existed but were explained by
differences in protein binding. For example, the serotonin 1A (5-HT1A)
receptor antagonist (3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-
2H-chromene-5-carboxamide (NAD-299) was shown to possess about
10-fold higher in vivo potency in monkeys than in humans, which could
be accounted for by a 10-fold higher plasma free fraction (Andrée et al.,
2003). In contrast, it was found that three structurally related inverse
agonists for the GABAA receptors had EC50 values in human that are a
third to a fifth of those in rats and rhesus monkeys, which could not be
Fig. 2. Individual LY2940094 plasma concentrations over
time by dose in human subjects after single oral adminis-
tration. Vertical lines are drawn to represent the timing of
the two post-dose scans.
TABLE 1
Mean (%CV) plasma noncompartmental LY2940094 pharmacokinetic parameters
by dose after single oral administration to human subjects
Dose n Cmax Tmax
a AUC0–28.5
mg ng/ml h h*ng/ml
4 3 7.93 (44.2) 6.00 (13.1) 63.4 (27.5)
10 3 22.4 (24.7) 4.48 (0.8) 176 (24.0)
20 2 38.5 NC 2.32 NC 316 NC
40 4 102 (26.2) 6.00 (12.7) 811 (16.3)
AUC0–28.5 = area under the plasma concentration–time curve from 0–28.5 hours after dose
administration; NC, not calculated; Tmax = time of maximum concentration.
aMedian.
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accounted for by differences in protein binding or binding affinity
(Atack et al., 2010; Eng et al., 2010).
In our studies, the LY2940094 NOP RO EC50 values in rats and humans
were approximately 2-fold apart; 5.75 and 2.64–3.46 ng/ml, respectively.
We assessed the binding affinity of LY2940094 in the membrane of
Chinese hamster ovary cells expressing recombinant human NOP receptor
and membranes isolated from whole rat brain with Ki values of 0.11 and
0.71 nM, respectively (Statnick et al., 2016). The free fraction in plasmawas
also assessed in both species: 0.89%and 0.56%, respectively. Correcting the
rat NOP RO EC50 value by both factors gives a human-equivalent EC50 of
0.56 ng/ml, overpredicting the human RO potency by 5-fold.
A larger dataset for different receptor types and ligands would be needed
before generalized translatability conclusions can be made. However, it is
clear that a few-fold error in either direction should be expected. In this
light, rats were reasonably predictive of human potency of NOP RO and
can thus support using preclinical RO data to help design early clinical
studies. Contributing factors to translation error include relatively imprecise
in vitro methods as well as differences in the methods used to assess RO.
Brain Penetration and RO Kinetics. Multiple pieces of evidence
suggest that LY2940094 equilibrates across the blood-brain barrier
quickly, likely through passive diffusion. Data generated in our
laboratories demonstrated that LY2940094 exhibited fast, passive
permeability with high partitioning in Madin-Darby canine kidney cells,
andwas not a P-glycoprotein substrate (unpublished). Consistentwith these
results, plasma and brain concentrations were generally parallel in rats (Fig.
1B). Furthermore, during the model building of human data, we confirmed
that the EC50 values separately estimated after the first and second postdose
scans were quite similar, suggesting a direct relationship between NOP
RO and plasma concentrations with no hysteresis or lag, a phenomenon
consistent with rapid equilibration between brain and plasma.
LY2940094 Pharmacokinetics, NOP RO, and Dose Selection.
Overall, our PET study in healthy volunteers demonstrated brain
penetrance and specific target engagement of NOP receptors after single
oral doses (4–40 mg) of LY2940094. The NOP RO increased with dose
and concentration, and was generally higher at the first postdose PET
scan (2.5 hours) compared with the second (26.5 hours). The NOP RO
levels appeared similar at the 20- and 40-mg doses at approximately 80%.
The RO remained high 26.5 hours after the 40-mg dose (above 70%).
On a plasma LY2940094 concentration basis, LY2940094 potently
occupied the NOP receptors, with EC50 values consistent across ROIs,
ranging between 2.64 and 3.46 ng/ml. Unlike the relationship with dose,
the LY2940094 concentration–RO relationship clearly suggests that
higher drug levels would produce an NOP RO approaching 100%,
consistent with rat data. The discrepancy can be explained by
Fig. 3. Sample image of [11C]NOP-1A uptake in the same
human subject at baseline and at 2.5 hours and 26.5 hours
after oral dosing of LY2940094 (40 mg), respectively.
TABLE 2
Regional NOP receptor occupancy values (%) by time point and LY2940094 dose after single oral administration to
human subjects
Model: Occupancy (%) = Emax * Concentration/(EC50 + Concentration); additive random subject.
Region of Interest
Dose





















Mean 48.8 38.9 74.4 30.2 89.0 62.4 86.5 76.6
S.D. 42.6 17.3 13.0 14.4 12.6 26.3 7.66 8.69
Occipital cortex
Mean 44.1 39.1 73.3 23.1 82.5 56.7 83.2 74.0
S.D. 42.3 15.0 13.4 19.9 18.2 27.8 7.13 5.54
Putamen
Mean 51.3 43.9 65.1 27.5 80.6 56.9 80.9 71.5
S.D. 34.6 13.5 17.5 18.7 13.7 28.5 8.12 7.92
Thalamus
Mean 49.3 42.7 66.5 29.5 82.5 60.0 83.7 75.5
S.D. 40.4 14.2 17.4 13.9 13.0 21.1 7.25 8.49
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LY2940094 plasma levels during the PET scans. LY2940094 absorp-
tion lagged by 1 to 2 hours and peaked 2 to 6 hours after oral dosing.
Although the intent was for the first postdose scan to concur with the
peak drug levels, the PET scan largely preceded the peak in most
subjects, oftentimes starting at the beginning of the rising phase of the
LY2940094–concentration relationship due to the significant absorp-
tion lag time (Fig. 2). Thus, the dose–RO relationship significantly
underestimates the potency of LY2940094 at peak levels. By chance, the
drug levels during the first postdose scan in the 20- and 40-mg dose
groups were similar and hence the RO was similar (Table 2).
Given the apparent quick equilibration of LY2940094 and constant RO
potency over time, NOP RO can be predicted from LY2940094 plasma
concentration, using the established concentration–RO relationship. Given
this relationship, we predict that the RO at mean observed peak concen-
tration for the doses of 4, 10, 20, and 40 mg averaged over the four tested
regions to be 73%, 88%, 93%, and 97%, respectively. Similarly, the
plasma LY2940094 concentration 24 hours after dose administration is
consistent with 28%, 49%, 65%, and 82%, respectively.
We measured RO after a single dose of LY2940094. However, the
RO after multiple-dose administration is of greater interest for a drug
intended for chronic administration. The data in this study alone are
inadequate to make such prediction, as a multiple-dose pharmacoki-
netic examination would be necessary. However, it is clear from the
concentration data up to 28.5 hours after dose administration that the
terminal half-life of LY2940094 is significantly in excess of 24 hours;
thus, a significant accumulation of 2-fold or higher is to be expected
upon once-daily dosing of LY2940094. Accounting for 2-fold concen-
tration accumulation, RO at trough levels would likely be in the vicinity
of 90%. If NOP is similar to other G protein-coupled receptors such as
dopamine D2 receptor antagonists as antipsychotic agents, a level of
occupancy between 50% and 90% is associated with clinically effica-
cious doses (Grimwood and Hartig, 2009).
In rats, LY2940094 reversed thewell-documented hypothermic effect of
theNOP agonist 8-[(1S,3aS)-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl]-1-
phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro-64-6198) 2 hours after dose
administration at 0.1 and 0.3 mg/kg, doses that are consistent with 50% to
80% NOP RO in our study (Toledo et al., 2014). Therefore, a 40-mg
once-daily dose of LY2940094, producing NOP RO in excess of 80%
throughout the dosing interval, is likely sufficient to test the therapeutic
hypotheses of LY2940094, but a lower dose may also produce such a level
of RO. Based on this information, a 40-mg daily dose of LY2940094 was
recently used in a proof-of-concept study ofmajor depressive disorder (Post
et al., 2015),whichwas conducted after the studiesmentioned in this report.
In that study, an 8-week treatment with a once-daily 40-mg dose of
LY2940094 provided some evidence of antidepressant effect (Post et al.,
2015), further supporting the current hypothesis.
Conclusion
The [11C]NOP-1A tracer has proven useful for the assessment of the
relationship between NOP RO, dose, and plasma concentration for the
newly discovered NOP antagonist LY2940094. LY2940094 penetrates
Fig. 4. Relationship between NOP RO and LY2940094 plasma concentration after single oral administration to human subjects in (A) prefrontal cortex, (B) occipital cortex,
(C) putamen, and (D) thalamus (data from 12 subjects).
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the brain with apparent quick equilibration. Rat NOP RO potency was
reasonably predictive of human potency. At oral doses that appeared safe
in human volunteers (4–40 mg), LY2940094 occupied up to a mean
of 87% at 2.5 hours after dose administration, with an expectation of
achieving approximately 97% at peak levels in various regions of the
brain. The plasma concentration potency (EC50) ranged between
2.64 and 3.46 ng/ml. At this potency and pharmacokinetics, a 40-mg
LY2940094 dose would be expected to maintain NOP RO above 80%
throughout the dosing interval upon once-daily oral dosing, a dose that is
appropriate to test the therapeutic hypotheses in future studies.
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TABLE 3
Parameter estimates by Emax model for LY2940094 plasma concentration-receptor
occupancy (%) after single oral administration to human subjects





EC50 (ng/ml) 2.94 0.512 1.81 4.07
Residual S.D. (%) 6.91 1.46 3.70 10.1
Intersubject S.D. (%) 12.5 2.98 5.96 19.1
Occipital cortex
Emax 100% (fixed)
EC50 (ng/ml) 3.46 0.685 1.96 4.97
Residual S.D. (%) 7.81 1.66 4.14 11.5
Intersubject S.D. (%) 13.9 3.35 6.48 21.2
Putamen
Emax 100% (fixed)
EC50 (ng/ml) 2.97 0.572 1.71 4.23
Residual S.D. (%) 5.77 1.25 3.02 8.52
Intersubject S.D. (%) 17.0 3.76 8.76 25.3
Thalamus
Emax 100% (fixed)
EC50 (ng/ml) 2.64 0.480 1.58 3.70
Residual S.D. (%) 5.42 1.18 2.82 8.03
Intersubject S.D. (%) 15.42 3.44 7.84 23.0
Emax, maximum % NOP receptor occupancy; CI, confidence interval; EC50, LY2940094
concentration that induces 50% receptor occupancy.
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